ACE-031 — Vendor Pricing & Purity Guide
Research Overview
ACE-031 is a soluble form of the ActRIIB receptor (activin receptor type IIB) that acts as a decoy receptor, binding and neutralizing myostatin and activin before they can signal through cell-surface receptors. By trapping these muscle-growth inhibitors, ACE-031 produces significant muscle hypertrophy and increased bone density.
ACE-031 reached Phase II clinical trials for Duchenne muscular dystrophy but was discontinued due to minor bleeding events (epistaxis, telangiectasias). The closely related compound ACE-2494 and similar ActRIIB traps continue in development for muscle-wasting conditions.
Key Research Findings
- •Increased lean muscle mass and bone density in Phase I healthy volunteer studies
- •Reached Phase II for Duchenne muscular dystrophy before discontinuation
- •Acts as myostatin/activin 'trap' — broader inhibition than myostatin-only blockers
- •Discontinued due to minor vascular side effects (epistaxis, telangiectasias)
- •Related ActRIIB-trap compounds continue in clinical development
Research Dosage Protocols
ACE-031 was administered as subcutaneous injection (1-3 mg/kg every 2 weeks) in clinical trials. Research-grade ACE-031 is a recombinant protein requiring careful cold-chain handling.
For research reference only. Not medical advice. Not for human consumption.
Price Comparison (3 products from 3 vendors)
| Vendor | Price | Stock |
|---|---|---|
| Swiss Chems | $138.95 $138.95/mg 1mg vial | In Stock |
| Biotech Peptides | $161.00 $161.00/mg 1mg vial | In Stock |
| Core Peptides | $173.00 $173.00/mg 1mg vial | In Stock |
Frequently Asked Questions
What is ACE-031?
ACE-031 is a soluble ActRIIB receptor that traps myostatin and activin, removing natural limits on muscle growth. It reached Phase II trials for DMD but was discontinued due to vascular side effects.